Cargando…
Screening for NAFLD—Current Knowledge and Challenges
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of abnormal liver function tests worldwide, with an estimated prevalence ranging between 19–46% in the general population. Of note, NAFLD is also expected to become a leading cause of end-stage liver disease in the next decades. Give...
Autores principales: | Forlano, Roberta, Sigon, Giordano, Mullish, Benjamin H., Yee, Michael, Manousou, Pinelopi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10144613/ https://www.ncbi.nlm.nih.gov/pubmed/37110194 http://dx.doi.org/10.3390/metabo13040536 |
Ejemplares similares
-
Applying Lipidomics to Non-Alcoholic Fatty Liver Disease: A Clinical Perspective
por: Huang, Jian, et al.
Publicado: (2023) -
THU642 Progression To Cirrhosis And All-cause Mortality Are Increased In Postmenopausal Women With NAFLD
por: Izzi-Engbeaya, Chioma, et al.
Publicado: (2023) -
Gut Microbiota—A Future Therapeutic Target for People with Non-Alcoholic Fatty Liver Disease: A Systematic Review
por: Forlano, Roberta, et al.
Publicado: (2022) -
Current and future pharmacological therapies for managing cirrhosis and its complications
por: Kockerling, David, et al.
Publicado: (2019) -
The Intestinal Barrier and Its Dysfunction in Patients with Metabolic Diseases and Non-Alcoholic Fatty Liver Disease
por: Forlano, Roberta, et al.
Publicado: (2022)